Ethics Board Needed to Help FDA With Postmarket Risk-Benefit Assessments: NEJM Report

Drug Industry Daily
An independent ethics advisory board is needed to help the FDA asses the risks and benefits of approved drugs and firm up its decisionmaking on postmarket safety issues, according to a new report.

To View This Article:


Subscribe To Drug Industry Daily